Developing a selective-separation polymer for biopharmaceuticals

MIP Technologies AB (Lund, Sweden; www.miptechnologies.com) has entered into a collaboration with Sanofi-aventis (Paris, France; en.sanofi-aventis.com) for the development of new molecularly imprinted polymers (MIPs) for the analysis of pharmacologically active peptides from plasma samples. MIP Technologies will use a number of its patented molecular imprinting methods in the development of the polymers. The use of MIPs for selective recognition of peptides and proteins is a novel area that will open up the technology to numerous applications in the diagnostic, pharmaceutical and biopharmaceutical industries. “This collaboration with Sanofi-aventis is both exciting and challenging,” said Anthony Rees, CEO at MIP Technologies. “We are looking to move into the development of peptide-selective MIPs, which represents a valuable piece of the separations market and has applications in analytical, preparative and process scale separations. Peptide-selective MIPs are particularly relevant for MIP Technologies since we hold important patents in this area. The added benefit of being able to address a large, new global market for molecularly imprinted polymers represents a significant commercial opportunity for the company.” Sanofi-aventis…